ScripThe two biggest biopharmaceutical initial public offerings in the US so far in 2023 occurred during the first week of May, although the largest of the two was a consumer health care spinout from a dru
ScripBiotechnology stocks in the US are still trading lower year-to-date, but valuations have risen significantly in April, suggesting that perhaps the winter chill hovering over the industry is beginning
ScripStrong clinical trial readouts can lead to surging stock prices and big follow-on public offerings (FOPOs), and in a less rocky market failed trial readouts mean that a biopharma company’s stock price